IGC Pharma, Inc. (IGC) vs TransCode Therapeutics Inc. (RNAZ)

IGC Pharma, Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. IGC Pharma, Inc. and TransCode Therapeutics Inc. are of similar size ($29.1M and $27.9M). TransCode Therapeutics Inc. has the higher net margin (0.00% vs −795.5%) and the higher return on invested capital (0.00% vs −91.5%). Across the 13 metrics below, TransCode Therapeutics Inc. leads on 9 and IGC Pharma, Inc. on 4.

Valuation

Metric IGC RNAZ Biotechnology median
P/E n/m n/m 7.88
P/S 25.52 n/m 11.47
P/B 4.58 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.15 0.74
EV/Sales 26.18 n/m 10.73
Earnings yield (32.14%) (3,098.82%) (28.84%)
Free cash flow yield (20.24%) (1,398.93%) (23.03%)

Profitability

Metric IGC RNAZ Biotechnology median
Gross margin 32.33% 0.00% 65.16%
Operating margin (912.44%) 0.00% 0.00%
Net margin (795.46%) 0.00% 0.00%
Free cash flow margin (516.53%) 0.00% 0.00%
Return on equity (143.46%) 429.61% (57.72%)
Return on assets (100.44%) (58.12%) (49.22%)
Return on invested capital (91.53%) 0.00% 0.00%

Growth

Metric IGC RNAZ Biotechnology median
Revenue growth (TTM) (13.38%) — 5.64%
EPS growth (last fiscal year) 57.85% 96.02% —
Revenue growth, 5-year CAGR (20.77%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IGC RNAZ Biotechnology median
Debt to equity 0.18 0.00 0.00
Current ratio 0.39 1.97 4.73
Net debt to EBITDA 0.04 0.64 0.96

Dividend

Metric IGC RNAZ Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IGC RNAZ Biotechnology median
Market cap 29.11m 27.94m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack